Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ovid Therapeutics (OVID) Operating Expenses (2020 - 2025)

Ovid Therapeutics (OVID) has disclosed Operating Expenses for 6 consecutive years, with $12.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Operating Expenses fell 5.55% year-over-year to $12.7 million, compared with a TTM value of $47.5 million through Sep 2025, down 32.15%, and an annual FY2024 reading of $62.5 million, up 4.66% over the prior year.
  • Operating Expenses was $12.7 million for Q3 2025 at Ovid Therapeutics, up from $11.3 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $31.8 million in Q1 2021 and bottomed at $10.8 million in Q4 2024.
  • Average Operating Expenses over 5 years is $15.8 million, with a median of $14.2 million recorded in 2023.
  • The sharpest move saw Operating Expenses skyrocketed 56.82% in 2021, then tumbled 53.63% in 2022.
  • Year by year, Operating Expenses stood at $26.4 million in 2021, then crashed by 53.63% to $12.2 million in 2022, then skyrocketed by 50.01% to $18.3 million in 2023, then plummeted by 41.09% to $10.8 million in 2024, then rose by 17.2% to $12.7 million in 2025.
  • Business Quant data shows Operating Expenses for OVID at $12.7 million in Q3 2025, $11.3 million in Q2 2025, and $12.7 million in Q1 2025.